S&P 500   3,323.00 (+0.04%)
DOW   29,164.29 (-0.08%)
QQQ   224.28 (+0.18%)
AAPL   318.79 (+0.34%)
FB   220.44 (-0.40%)
MSFT   166.18 (+0.29%)
GOOGL   1,487.82 (+0.25%)
AMZN   1,886.12 (-0.07%)
NVDA   252.67 (+1.05%)
BABA   219.04 (-1.50%)
MU   59.28 (+0.19%)
GE   11.80 (+3.78%)
TSLA   567.78 (-0.31%)
AMD   51.57 (+0.27%)
T   38.66 (-0.97%)
F   9.11 (-0.55%)
NFLX   342.30 (+5.00%)
DIS   142.21 (-1.25%)
GILD   63.83 (+0.63%)
S&P 500   3,323.00 (+0.04%)
DOW   29,164.29 (-0.08%)
QQQ   224.28 (+0.18%)
AAPL   318.79 (+0.34%)
FB   220.44 (-0.40%)
MSFT   166.18 (+0.29%)
GOOGL   1,487.82 (+0.25%)
AMZN   1,886.12 (-0.07%)
NVDA   252.67 (+1.05%)
BABA   219.04 (-1.50%)
MU   59.28 (+0.19%)
GE   11.80 (+3.78%)
TSLA   567.78 (-0.31%)
AMD   51.57 (+0.27%)
T   38.66 (-0.97%)
F   9.11 (-0.55%)
NFLX   342.30 (+5.00%)
DIS   142.21 (-1.25%)
GILD   63.83 (+0.63%)
S&P 500   3,323.00 (+0.04%)
DOW   29,164.29 (-0.08%)
QQQ   224.28 (+0.18%)
AAPL   318.79 (+0.34%)
FB   220.44 (-0.40%)
MSFT   166.18 (+0.29%)
GOOGL   1,487.82 (+0.25%)
AMZN   1,886.12 (-0.07%)
NVDA   252.67 (+1.05%)
BABA   219.04 (-1.50%)
MU   59.28 (+0.19%)
GE   11.80 (+3.78%)
TSLA   567.78 (-0.31%)
AMD   51.57 (+0.27%)
T   38.66 (-0.97%)
F   9.11 (-0.55%)
NFLX   342.30 (+5.00%)
DIS   142.21 (-1.25%)
GILD   63.83 (+0.63%)
S&P 500   3,323.00 (+0.04%)
DOW   29,164.29 (-0.08%)
QQQ   224.28 (+0.18%)
AAPL   318.79 (+0.34%)
FB   220.44 (-0.40%)
MSFT   166.18 (+0.29%)
GOOGL   1,487.82 (+0.25%)
AMZN   1,886.12 (-0.07%)
NVDA   252.67 (+1.05%)
BABA   219.04 (-1.50%)
MU   59.28 (+0.19%)
GE   11.80 (+3.78%)
TSLA   567.78 (-0.31%)
AMD   51.57 (+0.27%)
T   38.66 (-0.97%)
F   9.11 (-0.55%)
NFLX   342.30 (+5.00%)
DIS   142.21 (-1.25%)
GILD   63.83 (+0.63%)
Log in
(Ad)
In my 40+ year career, I have yet to see a convergence of three significant factors that has me this optimistic about the stock market. I believe 2020 could deliver the largest wealth-building opportunity in a generation. Don't miss out on this historic year.

NASDAQ:CRNX - Crinetics Pharmaceuticals Stock Price, Forecast & News

$22.76
+0.08 (+0.35 %)
(As of 01/23/2020 02:43 PM ET)
Today's Range
$22.28
Now: $22.76
$22.81
50-Day Range
$19.33
MA: $23.33
$26.46
52-Week Range
$14.33
Now: $22.76
$28.81
Volume2,235 shs
Average Volume69,374 shs
Market Capitalization$551.25 million
P/E RatioN/A
Dividend YieldN/A
Beta1.1
Crinetics Pharmaceuticals, Inc, a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is CRN00808, an oral selective nonpeptide somatostatin receptor type 2 biased agonist, which is in Phase I clinical trials used for the treatment of acromegaly. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CRNX
CUSIPN/A
CIKN/A
Phone858-450-6464

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.43 million
Book Value$6.67 per share

Profitability

Net Income$-27,110,000.00

Miscellaneous

Employees47
Market Cap$551.25 million
Next Earnings Date3/11/2020 (Estimated)
OptionableNot Optionable

Receive CRNX News and Ratings via Email

Sign-up to receive the latest news and ratings for CRNX and its competitors with MarketBeat's FREE daily newsletter.


(Ad)

One of the best ways to double, if not triple your investment in 2020 will be found in tech stocks. Especially those involved with the 5G rollout, where we're still finding undervalued opportunities. In our latest special report, we detail these and other hot tech stocks that should be part of your portfolio right now.

Crinetics Pharmaceuticals (NASDAQ:CRNX) Frequently Asked Questions

What is Crinetics Pharmaceuticals' stock symbol?

Crinetics Pharmaceuticals trades on the NASDAQ under the ticker symbol "CRNX."

How were Crinetics Pharmaceuticals' earnings last quarter?

Crinetics Pharmaceuticals Inc (NASDAQ:CRNX) issued its quarterly earnings results on Tuesday, November, 12th. The company reported ($0.60) EPS for the quarter, missing analysts' consensus estimates of ($0.57) by $0.03. The company earned $0.51 million during the quarter, compared to analysts' expectations of $0.33 million. View Crinetics Pharmaceuticals' Earnings History.

When is Crinetics Pharmaceuticals' next earnings date?

Crinetics Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, March 11th 2020. View Earnings Estimates for Crinetics Pharmaceuticals.

What price target have analysts set for CRNX?

3 analysts have issued 1 year target prices for Crinetics Pharmaceuticals' shares. Their forecasts range from $35.00 to $40.00. On average, they expect Crinetics Pharmaceuticals' stock price to reach $37.33 in the next twelve months. This suggests a possible upside of 64.0% from the stock's current price. View Analyst Price Targets for Crinetics Pharmaceuticals.

What is the consensus analysts' recommendation for Crinetics Pharmaceuticals?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Crinetics Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Crinetics Pharmaceuticals.

What are Wall Street analysts saying about Crinetics Pharmaceuticals stock?

Here are some recent quotes from research analysts about Crinetics Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Crinetics Pharmaceuticals Inc is a clinical stage pharmaceutical company. It focuses on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's product pipeline consists of CRN00808 for the treatment of Acromegaly, CRN02481 for the treatment of Hyperinsulinemias and CRN01941 for the treatment of Neuroendocrine Tumors which are in clinical stage. Crinetics Pharmaceuticals Inc is based in San Diego, United States. " (1/22/2020)
  • 2. HC Wainwright analysts commented, "Valuation; reiterate Buy rating. Our $35 price target for Crinets is based on our sum-of-the-parts NPV valuation based on each of the company’s ongoing products. Our DCF model utilizes a discount rate of 12.2% based on the company’s WACC (Beta of 1.1, equity risk premium of 6.7%)." (4/16/2019)

Has Crinetics Pharmaceuticals been receiving favorable news coverage?

Media headlines about CRNX stock have been trending somewhat positive this week, InfoTrie Sentiment reports. The research group identifies negative and positive press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Crinetics Pharmaceuticals earned a coverage optimism score of 1.8 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View News Stories for Crinetics Pharmaceuticals.

Are investors shorting Crinetics Pharmaceuticals?

Crinetics Pharmaceuticals saw a decrease in short interest during the month of December. As of December 31st, there was short interest totalling 1,840,000 shares, a decrease of 9.8% from the December 15th total of 2,040,000 shares. Based on an average daily volume of 55,500 shares, the short-interest ratio is presently 33.2 days. Approximately 13.2% of the shares of the company are sold short. View Crinetics Pharmaceuticals' Current Options Chain.

Who are some of Crinetics Pharmaceuticals' key competitors?

What other stocks do shareholders of Crinetics Pharmaceuticals own?

Who are Crinetics Pharmaceuticals' key executives?

Crinetics Pharmaceuticals' management team includes the folowing people:
  • Dr. R. Scott Struthers, Founder, Pres, CEO & Director (Age 57)
  • Mr. Marc J. C. Wilson, CFO & Sec. (Age 40)
  • Dr. Alan S. Krasner, Chief Medical Officer (Age 56)
  • Dr. Stephen F. Betz, Co-Founder & VP of Biology (Age 53)

When did Crinetics Pharmaceuticals IPO?

(CRNX) raised $80 million in an initial public offering on Wednesday, July 18th 2018. The company issued 5,000,000 shares at $15.00-$17.00 per share. J.P. Morgan, Leerink Partners and Piper Jaffray acted as the underwriters for the IPO.

How do I buy shares of Crinetics Pharmaceuticals?

Shares of CRNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Crinetics Pharmaceuticals' stock price today?

One share of CRNX stock can currently be purchased for approximately $22.76.

How big of a company is Crinetics Pharmaceuticals?

Crinetics Pharmaceuticals has a market capitalization of $551.25 million and generates $2.43 million in revenue each year. The company earns $-27,110,000.00 in net income (profit) each year or ($2.23) on an earnings per share basis. Crinetics Pharmaceuticals employs 47 workers across the globe.View Additional Information About Crinetics Pharmaceuticals.

What is Crinetics Pharmaceuticals' official website?

The official website for Crinetics Pharmaceuticals is http://www.crinetics.com/.

How can I contact Crinetics Pharmaceuticals?

Crinetics Pharmaceuticals' mailing address is 10222 Barnes Canyon Road Building #2, San Diego CA, 92121. The company can be reached via phone at 858-450-6464 or via email at [email protected]


MarketBeat Community Rating for Crinetics Pharmaceuticals (NASDAQ CRNX)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  68 (Vote Outperform)
Underperform Votes:  82 (Vote Underperform)
Total Votes:  150
MarketBeat's community ratings are surveys of what our community members think about Crinetics Pharmaceuticals and other stocks. Vote "Outperform" if you believe CRNX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CRNX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/23/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel